Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
Following our recent business combination with OnCore Biopharma, Inc., ("OnCore") we intend to focus our efforts on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. Our strategy incorporates our heritage and expertise in RNAi combined with the newly acquired assets and expertise through the OnCore merger. We believe that, as a result of the merger, Tekmira will be well positioned to capitalize on the HBV global market opportunity. Our current HBV pipeline consists of 9 drugs and drug candidates, with eight unique mechanisms of action. ... More ...
Where does TKMR fit in the risk graph?
|Annual EPS Est:||$-0.99|
|Quarterly EPS Est:||-0.39|